Next wave of innovation in Alzheimer’s disease therapeutics: The value of novel active transport mechanisms
Utilizing active transport mechanisms, such as the Brainshuttle™ technology, to achieve rapid and efficient amyloid clearance may unlock the full potential of disease modification with Aβ-targeting monoclonal antibodies in AD. Active transport mechanisms could also be used in other large molecule delivery systems to improve distribution of drugs as well as efficacy and safety profiles.
Authors
- Roberto Villaseñor (ORCID: https://orcid.org/0000-0002-0244-1091)
- Luka Kulic (ORCID: https://orcid.org/0000-0003-3427-9436)
- Scarlett J. Barker (ORCID: https://orcid.org/0000-0003-2237-1569)
- Jens Niewoehner
- Catherine J. Mummery
Institutions
- Roche (Switzerland) (CH)
- Roche Pharma AG (Germany) (DE)
- Denali Therapeutics (United States) (US)
- National Hospital for Neurology and Neurosurgery (GB)
- University College London (GB)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70859_104284
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00